Free Cash Flow. Free Cash Flow of at least (i) ($2,000,000.00) for the calendar quarter ending Xxxxx 00, 0000, (xx) ($6,500,000.00) for the calendar quarter ending June 30, 2012, (iii) ($2,000,000.00) for each of the calendar quarters ending September 30 and December 31, 2012, and (iv) $2,000,000.00 for the calendar quarter ending March 31, 2013, and for each calendar quarter thereafter, to be tested in each case as of the last day of each calendar quarter.”
Appears in 1 contract
Samples: Loan Modification Agreement (Sagent Pharmaceuticals, Inc.)
Free Cash Flow. Free Cash Flow of at least (i) ($2,000,000.00) for the calendar quarter ending Xxxxx 00, 0000, (xx) ($6,500,000.00) for the calendar quarter ending June 30, 2012, (iii) ($2,000,000.00) for each of the calendar quarters ending September 30 March 31, 2012 and December 31June 30, 2012, and (ivii) $2,000,000.00 for the calendar quarter ending March 31, 2013, and for each calendar quarter thereafter, to be tested in each case as of the last day of each calendar quarter.”
Appears in 1 contract
Samples: Loan and Security Agreement (Sagent Pharmaceuticals, Inc.)
Free Cash Flow. Free Cash Flow of at least (i) ($2,000,000.00) for the calendar quarter ending Xxxxx 00, 0000, (xx) ($6,500,000.00) for the calendar quarter ending June 30, 2012, (iii) ($2,000,000.00) for each of the calendar quarters ending September 30 30, 2012 and December 31, 2012, and (iv) $2,000,000.00 for the calendar quarter ending March 31, 2013, and for each calendar quarter thereafter, to be tested in each case as of the last day of each calendar quarter.”” and inserting in lieu thereof the following:
Appears in 1 contract
Samples: Loan Modification Agreement (Sagent Pharmaceuticals, Inc.)
Free Cash Flow. Free Cash Flow of at least (i) ($2,000,000.00) for the calendar quarter ending Xxxxx 00, 0000, (xx) ($6,500,000.00) for the calendar quarter ending June 30, 2012, (iii) ($2,000,000.00) for each of the calendar quarters ending September 30 March 31, 2012 and December 31June 30, 2012, and (ivii) $2,000,000.00 for the calendar quarter ending March 31, 2013, and for each calendar quarter thereafter, to be tested in each case as of the last day of each calendar quarter.”” and inserting in lieu thereof the following:
Appears in 1 contract
Samples: Loan Modification Agreement (Sagent Pharmaceuticals, Inc.)
